FDA Begins Review of Biogen's Hemophilia B Drug

Biogen Idec (NASDAQ: BIIB  ) announced today that the FDA has accepted the company's new hemophilia B drug application and will begin its regulatory review. The review is expected to take 10 months, according to the AP.

Hemophilia B is a rare, inherited disorder in which the ability of a person's blood to clot is impaired.

Biogen's recombinant factor IX Fc fusion protein (rFIXFc) is a clotting factor that uses the company's FDA-approved proprietary monomeric Fc fusion technology to provide longer-lasting protection from bleeding.

"We are encouraged by the FDA's acceptance of our application, as we believe rFIXFc has the potential to transform the care of hemophilia B by allowing for less frequent injections and helping patients to maintain low annualized bleeding rates," Dr. Glenn Pierce, a senior vice president of Biogen Idec, is quoted as saying in the company press release. "We are working with the FDA to bring the first major treatment advance for the hemophilia B community in 15 years."

Not only does the drug potentially provide better protection from bleeding, but it can also significantly reduce the 100+ injections a year some hemophilia B patients now receive to aid clotting, according to Biogen Idec. The compay says B-LONG, the largest registrational phase 3 clinical study ever conducted for hemophilia B, supported these findings.

link


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2291909, ~/Articles/ArticleHandler.aspx, 10/22/2014 1:01:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement